Over the recent decade, immunotherapies aiming at PD-1/PD-L1 axis modification have obtained a series of remarkable discoveries in prognosis improvement of arduously to-treat solid tumors and are going to enter into the clinical practice of brain tumors. The gene discussed is PDCD1; the disease is brain neoplasm.